. Abolition of arteriolar dilation but not constriction to histamine in cremaster muscle of eNOS Ϫ/Ϫ mice. Am J Physiol Heart Circ Physiol 285: H493-H498, 2003. First published April 10, 2003 10.1152/ ajpheart.00071.2003.-Histamine increases the permeability of capillaries and venules but little is known of its precapillary actions on the control of tissue perfusion. Using gene ablation and pharmacological interventions, we tested whether histamine could increase muscle blood flow through stimulating nitric oxide (NO) release from microvascular endothelium. Vasomotor responses to topical histamine were investigated in second-order arterioles in the superfused cremaster muscle of anesthetized C57BL6 mice and null platelet endothelial cell adhesion molecule-1 (PECAM-1 Ϫ/Ϫ ) and null endothelial NO synthase (eNOS Ϫ/Ϫ ) mice aged 8-12 wk. Neither resting (17 Ϯ 1 m) nor maximum diameters (36 Ϯ 2 m) were different between groups, nor was the constrictor response (ϳ5 Ϯ 1 m) to elevating superfusate oxygen from 0 to 21%. For arterioles of C57BL6 and PECAM-1 Ϫ/Ϫ mice, cumulative addition of histamine to the superfusate produced vasodilation (1 nM-1 M; peak response, 9 Ϯ 1 m) and then vasoconstriction (10-100 M; peak response, 12 Ϯ 2 m). In eNOS Ϫ/Ϫ mice, histamine produced only vasoconstriction. In C57BL6 and PECAM-1 Ϫ/Ϫ mice, vasodilation was abolished with N -nitro-L-arginine (30 M); in all mice, vasoconstriction was abolished with nifedipine (1 M). Vasomotor responses were eliminated with pyrilamine (1 M; H1 receptor antagonist) yet remained intact with cimetidine (1 M; H2 receptor antagonist). These findings illustrate that the biphasic vasomotor response of mouse cremaster arterioles to histamine is mediated through H1 receptors on endothelium (NO-dependent vasodilation) as well as smooth muscle (Ca 2ϩ entry and constriction). Thus histamine can increase as well as decrease muscle blood flow, according to local concentration. However, when NO production is compromised, only vasoconstriction and flow reduction occur.
HISTAMINE IS FORMED from the decarboxylation of L-histidine, stored in mast cells and circulating basophils (4, 6, 11) , and released during tissue injury and inflammation. In the vasculature, histamine has been studied primarily in the context of modulating the permeability of capillaries and postcapillary venules (2, 3, 7, 15, 24) , implying a key role in modulating cell-cell adhesion (1, 8, 16, 21) . Histamine can also influence tissue blood flow. Histamine promotes arteriolar dilation (18, 20, 25) in a variety of tissues, whereas others have shown histamine to promote vasoconstriction (4, 15, 19, 22) . These dichotomous responses suggest that the actions of histamine on vessel diameter and tissue blood flow may depend upon its free concentration and to the vascular bed exposed. However, there is a paucity of information in a given vascular bed on the actions of histamine through a complete range of concentrations.
The initiation of vasomotor responses to histamine is mediated through H 1 and H 2 receptor subtypes (10) . However, despite the availability of selective pharmacological reagents, neither the presence of respective receptor subtypes nor the signaling pathways activated have been well characterized in the resistance vessels that control tissue blood flow. Whereas transgenic technology has enabled selective elimination of molecules that are integral to vascular cell signaling and adhesion [e.g., nitric oxide (NO) synthase (NOS) and platelet endothelial cell adhesion molecule-1 (PECAM-1; i.e., CD31)], little is known of whether gene ablation may influence the vasomotor effects of histamine in the microcirculation.
In the present study, experiments were performed in null PECAM-1 (PECAM-1 Ϫ/Ϫ ) and null endothelial NOS (eNOS Ϫ/Ϫ ) mice with reference to C57BL6 mice to determine whether genetically ablating these molecules would influence the actions of histamine on arterioles controlling blood flow in skeletal muscle. We tested the hypothesis that histamine would increase muscle blood flow through stimulating NO release from microvascular endothelium. Complimentary experiments used pharmacological interventions to resolve the receptor subtype and signaling pathways that mediate vasomotor responses through a range of histamine concentrations spanning six orders of magnitude and which encompass the initiation of vasodilation through closure of the arteriolar lumen.
MATERIALS AND METHODS
Mouse cremaster muscle preparation. Procedures were approved by the Animal Care and Use Committee of The John B. Pierce Laboratory and performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Control experiments were performed on male C57BL6 mice (25-30 g, n ϭ 28; Jackson Laboratories, Bar Harbor, ME). PECAM-1 Ϫ/Ϫ (n ϭ 10) (5), and eNOS Ϫ/Ϫ (n ϭ 11) (23) were bred from C57BL6 mice (backcrossed 12 times). All mice were 8 to 12 wk old at the time of study. Mice were housed at 24°C and maintained on a 12:12-h light/dark cycle with food and water ad libitum. Animals were anesthetized with pentobarbital sodium (50 mg/kg ip), which was supplemented as needed to prevent withdrawal from toe pinch. At the end of an experiment, the mice were euthanized with an intraperitoneal overdose of pentobarbital. The anesthetized mouse was placed supine on a clear acrylic platform. Esophageal temperature was maintained at 37-38°C by radiant heat. The left cremaster muscle was prepared as described (12) . Briefly, a midline incision was made in the left scrotal sac. Connective tissue was cleared, and the exposed muscle was opened longitudinally and separated from the testis, which was repositioned in the abdominal cavity. The muscle was spread evenly and pinned onto a pedestal of transparent Sylgard (Dow Corning; Midland, MI) while being superfused (5 ml/min) with bicarbonate-buffered physiological salt solution (PSS; 34°C, pH 7.4) of the following composition (in mM): 137 NaCl, 4.7 KCl, 1.2 MgSO4, 2 CaCl2, and 18 NaHCO3. The PSS reservoir was equilibrated with 5% CO2-95% N2 unless noted otherwise.
Intravital microscopy. The completed preparation was transferred to the stage of an intravital microscope (modified model 20T, Zeiss), equilibrated for 60 min and viewed with brightfield illumination (condensor numerical aperture 0.32). A drawing of the arteriolar network was made during this period. During experiments, arterioles were observed using a Zeiss UD 40 objective (numerical aperture 0.41) coupled to a video camera (model NC 70X, Dage-MTI; Michigan City, IN); total magnification on the video monitor (model PVM-132, Sony) was ϫ620. Vessel diameter was determined from the edges of the lumen with the use of a video caliper (modified model 321, Colorado Video; Boulder, CO) with spatial resolution Յ2 m. Data were acquired at 40 Hz with the use of a PowerLab system (model 8S, ADInstruments; Castle Hill, Australia) coupled to a personal computer.
Chemicals and reagents. Chemicals and reagents were purchased from Sigma Aldrich (St. Louis, MO). Final working concentrations are given after diluting stock solutions at least 100-fold in fresh PSS: histamine (1 nM to 100 M),
, L-arginine (L-Arg, 1 mM; biological substrate for NOS), sodium nitroprusside (SNP, 10 M; NO donor), and nifedipine (1 M; antagonist of L-type Ca 2ϩ channels). Nifedipine was first dissolved in ethanol (0.01% final concentration; vehicle controls had no effect on arteriolar diameter or reactivity).
Experimental protocols. Experimental manipulations were performed while observing second-order arterioles that were located in the central region of the cremaster muscle preparation and away from adjacent venules (12, 17) . One arteriole was studied in each mouse. Resting internal diameter was measured under control conditions and after elevating superfusate oxygen to 21% (with 5% CO2, balance N2) for 10 min. At the conclusion of each experiment, maximal diameter was recorded during topical application of SNP. The actions of histamine (concentration response, receptor subtype, and signaling pathways) were initially evaluated in arterioles from C57BL6 mice. The mouse genotype was then varied across experiments to avoid an order effect.
Vasomotor responses to histamine. The effect of changing histamine concentration was determined by cumulative addition (1 nM to 100 M) to the superfusion solution. At each concentration, arteriolar diameter was allowed to stabilize for at least 2 min and then recorded before the next increment. After the response to 100 M histamine, superfusion with control PSS was restored, and resting diameter typically recovered within ϳ25 min.
Histamine receptor antagonists. After the initial evaluation of and recovery from responses to histamine, pyrilamine was equilibrated for 20 min and the concentration-response relationship to histamine was reevaluated. Superfusion with control PSS was restored (ϳ30 min) and the histamine concentration-response relationship reevaluated (not different from control; data not shown). Cimetidine was then equilibrated for 20 min and the concentration-response relationship to histamine evaluated a final time.
Signaling pathways. Concentration-response relationships were first obtained under control conditions and arterioles recovered as described above. To investigate a role for NO in arteriolar responses, L-NNA was equilibrated for at least 30 min and vasomotor responses to incremental histamine concentrations were reevaluated. The specificity of NOS inhibition was determined by the addition of L-Arg to the PSS and reevaluation of the histamine concentrationresponse relationship. To investigate a role for Ca 2ϩ influx in vasoconstriction (10) , the response to 100 M histamine was recorded, control superfusion was restored until diameter recovered (ϳ20 min), and then histamine (100 M) and nifedipine were applied simultaneously. Superfusion with control PSS was then resumed for ϳ10 min and the response to 100 M histamine was reevaluated.
Data analysis. Data were analyzed using one-way repeated-measures ANOVA with Tukey post hoc comparisons (SigmaStat version 2.03; SPSS, Chicago, IL). Summary data are presented as means Ϯ SE. Values for n refer to the number of arterioles studied in as many mice. Differences between groups were accepted as statistically significant with P Ͻ 0.05.
RESULTS
The topology of arteriolar networks was similar between C57BL6, PECAM-1
, and eNOS Ϫ/Ϫ mice. Resting and maximal diameters of arterioles, as well as their constriction to elevated oxygen, were not different between groups (Table 1) . Cremaster preparations were stable for 4-5 h and arterioles were evaluated over 2-3 h. Vasomotor responses to histamine. In C57BL6 mice, arterioles dilated progressively as histamine concentration increased from 1 nM to 1 M, reaching a peak diameter (26 Ϯ 2 m) that was 58% of the maximum diameter obtained with SNP (Fig. 1) . Arterioles then constricted progressively as histamine concentration increased to 10 and 100 M. Peak constriction was typically accompanied by occlusion of the vessel lumen and blood flow ceased in ϳ50% of arterioles. In PECAM-1 Ϫ/Ϫ mice, arteriolar responses to histamine were similar to those of C57BL6 mice (Fig. 1) . Remarkably, only vasoconstriction was observed in eNOS Ϫ/Ϫ mice. For example, at 1 M histamine, arterioles of eNOS Ϫ/Ϫ mice constricted by ϳ10 m, whereas those from C57BL6 and PECAM-1 Ϫ/Ϫ mice dilated by a similar amount (Fig. 1) . Across all three strains of mice, there was no difference in the peak amplitude of vasoconstriction with 100 M histamine.
Histamine receptor antagonists. Neither pyrilamine nor cimetidine had a significant effect on resting diameter. In C57BL6 mice, both dilation and constriction of arterioles to histamine were inhibited by pyrilamine ( Fig. 2A) . In contrast, cimetidine had no effect on arteriolar dilations from 1 nM to 1 M histamine or constriction to 100 M histamine. However, cimetidine attenuated vasoconstriction to 100 M histamine. In PECAM-1 Ϫ/Ϫ and eNOS Ϫ/Ϫ mice, arteriolar responses to histamine were also inhibited completely by pyrilamine (Fig. 2B) .
Signaling pathways. In C57BL6 mice, arteriolar dilations at histamine concentrations of 1 nM to 1 M were reversed to constrictions in the presence of L-NNA (Fig. 3) , which otherwise had no significant affect on 22 Ϯ 4 m; n ϭ 4). Arteriolar constrictions at 10 and 100 M histamine were unaffected by L-NNA. The addition of L-Arg completely reversed the actions of L-NNA and restored vasodilation from 1 nM to 1 M histamine (Fig. 3) . In C57BL6 mice, nifedipine reversed vasoconstriction to vasodilation at 10 Ϫ4 M histamine (Fig. 4) . The vasoconstriction to 100 M histamine was restored after washout of nifedipine and return to resting diameter (Fig. 4) . In PECAM-1 Ϫ/Ϫ mice, arteriolar dilation and constriction to histamine were abolished by L-NNA and nifedipine, respectively (n ϭ 4; P Ͻ 0.05 vs. control). In eNOS Ϫ/Ϫ mice, arteriolar constriction was abolished by nifedipine (n ϭ 4; P Ͻ 0.05 vs. control).
DISCUSSION
The present study used gene ablation and pharmacological interventions to investigate the vasomotor actions of histamine in arterioles of the mouse cremaster muscle and to identify the underlying signaling pathways. Our findings show that histamine consistently produced vasodilation In C57BL6 and PECAM-1 Ϫ/Ϫ mice at nanomolar concentrations and vasoconstriction above micromolar concentrations. Remarkably, through the same range of concentrations, histamine produced only vasoconstriction in eNOS Ϫ/Ϫ mice. As indicated by the action of nifedipine in each strain of mice, constriction to histamine resulted from the activation of L-type Ca 2ϩ channels in arteriolar smooth muscle cells. The absence of vasodilation in eNOS Ϫ/Ϫ mice and its reversible abolition with L-NNA in C57BL6 and PECAM-1 Ϫ/Ϫ mice indicates that NO release fully accounts for the actions of histamine as a vasodilator in our experiments. In conduit arteries, smooth muscle relaxation in response to histamine is mediated through H 1 receptors on endothelial cells (4, 10) . In C57BL6 and PECAM-1 Ϫ/Ϫ mice, the inhibition of arteriolar dilation with pyrilamine and the lack of effect of cimetidine indicate that NO production is coupled to the activation of H 1 receptors on microvascular endothelium. Our finding that dilatory responses to SNP (an NO donor) were similar for arterioles of eNOS Ϫ/Ϫ , C57BL6, and PECAM-1 Ϫ/Ϫ mice indicates that the biological actions of NO were not different across these strains. Furthermore, it is unlikely that the vasodilation observed here is mediated through the release of prostaglandins or other endothelium-derived autacoids. We therefore conclude that eNOS is central to Fig. 2 . A: effects of receptor antagonists on histamine-induced vasomotor responses in arterioles. Both dilation and constriction observed in arterioles of C57BL6 mice (control; n ϭ 5) in response to histamine were abolished by pyrilamine (1 M). Cimetidine (1 M) had no effect except at the highest concentration of histamine. *P Ͻ 0.05, significant difference between histamine ϩ pyrilamine vs. histamine ϩ cimetidine or histamine alone. ϩP Ͻ 0.05, significant difference between histamine alone vs. histamine ϩ cimetidine. B: effect of pyrilamine on histamine-induced vasomotor responses in arterioles from PECAM-1 Ϫ/Ϫ and eNOS Ϫ/Ϫ mice (n ϭ 4 per group). All responses to histamine were abolished by pyrilamine. *P Ͻ 0.05, significant difference between histamine ϩ pyrilamine and histamine alone in both PECAM-1 Ϫ/Ϫ and eNOS Ϫ/Ϫ arterioles. ϩP Ͻ 0.05, significant difference between PECAM-1 Ϫ/Ϫ and eNOS Ϫ/Ϫ arterioles. the ability of histamine to dilate arterioles controlling blood flow to the mouse cremaster muscle.
In conduit arteries, H 1 receptors on smooth muscle cells are coupled to the G protein-phospholipase C pathway, leading to the activation of L-type Ca 2ϩ channels and an increase in intracellular Ca 2ϩ concentration (9, 10, 14) . Alternatively, the activation of H 2 receptors on smooth muscle stimulates the cAMP-adenylate cyclase pathway to promote relaxation (4, 10, 14) . Our finding that arteriolar constrictions to histamine were abolished by pyrilamine, and that cimetidine had negligible effect, indicates that histamine acted on arteriolar smooth muscle through the classic G protein, H 1 receptor-coupled pathway. We conclude that both constriction and dilation of arterioles are promoted through H 1 receptors and that H 2 receptors have little or no role in blood flow control in the microcirculation of mouse skeletal muscle.
Arteriolar responses to increasing histamine concentration were biphasic, with dilation at Յ1 M, followed by constriction at Ͼ1 M. However, inhibiting constriction with nifedipine unmasked a dilation that was otherwise overshadowed (Fig. 4) . In a reciprocal manner, genetic ablation of eNOS or pharmacological inhibition of NOS revealed constriction of arterioles at histamine concentrations that otherwise caused dilation (Figs. 1 and 3 ). These findings illustrate that competing responses of endothelium and smooth muscle to histamine can be active simultaneously with the prevailing histamine concentration determining which signaling pathway dominates the arteriolar vasomotor response. Whereas NO has been implicated as a key mediator of the integrity of capillary and venular endothelium (3, 13) , the present data illustrate that precapillary actions of histamine have pronounced effects on the control of tissue blood flow.
PECAM-1 is found predominantly in the lateral junctions between endothelial cells, where it acts in signal transduction and as a stabilizing link between endothelial cells (1, 16) . Activating H 1 receptors can lead to changes in vascular permeability (15) . Indeed, recent studies have shown that histamine promotes greater leakiness in endothelium of PECAM-1 Ϫ/Ϫ mice compared with C57BL6 mice (8) . However, the lack of PECAM-1 had no apparent effect on the vasomotor actions of histamine, because arteriolar responses in PECAM-1 Ϫ/Ϫ mice were similar to those observed in C57BL6 mice (Fig. 1) . This finding argues that genetic ablation in and of itself does not affect arteriolar responses to histamine in the mouse cremaster muscle. Furthermore, given that the vasomotor responses to histamine in eNOS Ϫ/Ϫ mice were indistinguishable from those in C57BL6 and PECAM-1 Ϫ/Ϫ mice in which NO production was inhibited with L-NNA, the present data provide a novel demonstration of how genetic ablation of eNOS recapitulates pharmacological inhibition of NOS activity.
In summary, arterioles from C57BL6 mice display a biphasic response to changes in histamine concentration, with vasodilation manifest at or below 1 M and vasoconstriction Ͼ1 M. Both dilation and constriction are mediated via H 1 receptors, with vasodilation dependent on NO production by endothelium and vasoconstriction promoted through the activation of L-type calcium channels in smooth muscle. With both cell layers activated simultaneously, the local concentration of histamine will dictate the actual vasomotor response. Thus moderate release of histamine (e.g., nM) would promote vasodilation and increase muscle blood flow. However, during impaired NO production (e.g., with endothelium dysfunction), the hyperemia associated with an inflammatory response will be abrogated. When histamine release is robust (e.g., exceeding M), arteriolar constriction will serve to reduce capillary hydrostatic pressure along with muscle blood flow, thereby minimizing fluid extravasation from capillaries and venules. In such a manner, histamine can serve as a key determinant of muscle blood flow and fluid filtration during injury and inflammation.
